Bone Biologics Corp

Bone Biologics Corp’s stock falls to $1.87 after a steep drop from a $7.74 peak, yet a decline in short interest hints at shifting investor optimism in its bone‑regeneration biotech strategy.

Bone Biologics Corp is a biotechnology company pioneering spinal fusion technology using recombinant human protein growth factors, with potential to revolutionize bone repair and regeneration applications.